|Articles|February 1, 2011

Applied Clinical Trials

  • Applied Clinical Trials-02-01-2011
  • Volume 20
  • Issue 2

Cardiovascular Drug Trial Discontinued

Merck's cardiovascular drug vorapaxar study was halted.

In mid-January, a combined Data Safety and Monitoring Board (DSMB) halted one of two Phase III trials of Merck's investigational anti-clotting drug vorapaxar because of increased risk of bleeding—specifically intracranial hemorrhage—in subjects with a history of stroke.

The TRACER study was being conducted by Duke Clinical Research Institute. It was fully enrolled in June 2010 and included 13,000 subjects with non-ST-segment-elevation acute coronary syndrome. TRA-2P, or TIMI 50 as the trial was also known, was fully enrolled in November 2009 and included 26,500 subjects who had previously experienced a heart attack. The study was being conducted by Brigham and Women's Hospital.

The DSMB instructed TRACER investigators to discontinue the study drug in subjects and begin close-out activities. For TRA-2P, investigators were told to discontinue the study drug in those who experienced a stroke prior to entering or during the course of the study. They could continue the study drug in those who entered the trial with a history of a previous heart attack or peripheral arterial disease, an estimated 75% of the subjects.

The www.clinicaltrials.gov identifier for the TRACER trial is NCT00527943, and NCT00526474 for TRA-2P. Peter Kim, PhD, President of Merck Research Laboratories, emphasized in a conference call that the goal of vorapaxar was to find "an antiplatelet agent that we could add on top of standard of care." Vorapaxar is one of the company's key programs in Phase III, and it had anticipated filing for approval this year. While financials were not discussed, at an estimated cost of $26,000 per subject in Phase III trials, this represents a $338 million hit to the company's bottom line.

Articles in this issue

almost 16 years ago

State Cash Fuels Growth in England

almost 16 years ago

Act Cover

almost 16 years ago

The FDA's Guidance on PRO

almost 16 years ago

H1N1 Influenza: Not to be Sneezed at

almost 16 years ago

New Approach to System Validation

Related to this article

The Next Evolution of Patient-Centered Trials Starts with Design
Decentralized trial success depends less on how far activities move away from sites than on matching each activity’s delivery model to participant burden, site readiness, and data integrity, using patient intelligence to decide where flexibility helps and where site-based care remains essential.
© putilov_denis - © putilov_denis - stock.adobe.com
Sponsors rigorously vet CROs for oncology expertise but rarely apply the same scrutiny to the IRB reviewing their trials, even though increasingly complex protocols require reviewers with substantive therapeutic knowledge, not just a rostered oncologist.